Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D) (TINSAL-T2D)
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate
Sponsor: Joslin Diabetes Center
Listed as NCT00392678, this PHASE2/PHASE3 trial focuses on Type 2 Diabetes and remains completed. Sponsored by Joslin Diabetes Center, it has been updated 11 times since 2006, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2_PHASE3
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2_PHASE3
-
May 2019 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — May 2019 [monthly]
Completed PHASE2_PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
-
Feb 2017 — Dec 2017 [monthly]
Completed PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2_PHASE3
First recorded
Oct 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Joslin Diabetes Center
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
For direct contact, visit the study record on ClinicalTrials.gov .